Clinical development of cardio-renal drugs

Cardiokine was a specialty pharmaceutical company founded around the licensing of Lixivaptan from Wyeth Pharmaceuticals in 2004. Lixivaptan is a sodium sparing diuretic that had completed multiple Phase I and Phase II trials.

CEO  Amber Salzman

Advent Contact  Shahzad Malik

Advent invested in the Series B in 2006. The Company was sold to Cornerstone Therapeutics in 2012.
Exited Investments
4 January 2012 in Cardiokine, Press Release

Cornerstone Therapeutics Acquires Cardiokine

Press Release.   January 04, 2012 07:30 ET Cornerstone Therapeutics Acquires Cardiokine CARY, NC--(Marketwire - Jan 4, 2012) - Cornerstone Therapeutics (NASDAQ: CRTX) •Cornerstone acquires worldwide rights to investigational therapy…
Read More
2 July 2007 in Cardiokine, Press Release

Biogen Idec and CardioKine partner to develop Lixivaptan, a novel Vasopressin Antagonist

Press Release.   Lixivaptan to enter Phase III clinical trial in 2007 in heart failure patients.   Cambridge, MA and Philadelphia, PA (July 2, 2007) – Biogen Idec (NASDAQ: BIIB)…
Read More